The main premise for the Recursion OS technology is to analyze and generate data from biological and chemical datasets on a large scale. To accomplish this, the foundation of the Recursion OS is set ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
Updated TUPELO results featured in a Presidential Plenary at CGA-IGC : Lisa Boardman, M.D., Professor of Medicine at Mayo Clinic, presented ...
9d
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
Webinar will include earnings updates and REC-4881 data as well as KOL and patient panels, presented live from CGA-IGC on Tuesday, November 3, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMTThird ...
Entered into a collaboration with Tempus giving Recursion access to over 20 petabytes of multimodal oncology data for the purpose of training causal AI models together with Recursion’s proprietary ...
Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair, ...
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics ...
Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...
These two companies could move in different directions over the medium term.
Recursion Pharmaceuticals (NASDAQ:RXRX) gained 7% on Monday after releasing encouraging Phase 2 results for REC-4881, its investigational therapy for familial adenomatous polyposis (FAP)—a hereditary ...
Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results